Blue Trust Inc. Sells 2,402 Shares of Elanco Animal Health Incorporated $ELAN

Blue Trust Inc. trimmed its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 37.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,936 shares of the company’s stock after selling 2,402 shares during the period. Blue Trust Inc.’s holdings in Elanco Animal Health were worth $56,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Allworth Financial LP increased its stake in Elanco Animal Health by 791.7% during the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock valued at $25,000 after acquiring an additional 2,090 shares during the period. Wealthquest Corp bought a new position in Elanco Animal Health during the first quarter valued at about $56,000. Covestor Ltd increased its stake in Elanco Animal Health by 510.9% during the first quarter. Covestor Ltd now owns 7,087 shares of the company’s stock valued at $74,000 after acquiring an additional 5,927 shares during the period. MRP Capital Investments LLC increased its stake in Elanco Animal Health by 60.0% during the first quarter. MRP Capital Investments LLC now owns 8,000 shares of the company’s stock valued at $84,000 after acquiring an additional 3,000 shares during the period. Finally, Parallel Advisors LLC increased its stake in Elanco Animal Health by 66.6% during the second quarter. Parallel Advisors LLC now owns 6,432 shares of the company’s stock valued at $92,000 after acquiring an additional 2,572 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. William Blair upgraded Elanco Animal Health from a “market perform” rating to an “outperform” rating in a research note on Thursday, June 26th. Wall Street Zen upgraded Elanco Animal Health from a “hold” rating to a “buy” rating in a research note on Saturday, July 5th. JPMorgan Chase & Co. upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $18.00 to $24.00 in a research note on Tuesday, October 7th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Elanco Animal Health in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $19.14.

Elanco Animal Health Stock Up 4.4%

Shares of ELAN opened at $21.42 on Friday. The company has a market capitalization of $10.64 billion, a P/E ratio of 24.91, a PEG ratio of 3.93 and a beta of 1.65. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $21.76. The business’s 50 day simple moving average is $18.90 and its 200-day simple moving average is $14.78.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.20 by $0.06. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.Elanco Animal Health’s revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, sell-side analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.